- New data show Roche’s subcutaneously administered crovalimab achieved disease control and was well-tolerated in people with paroxysmal nocturnal haemoglobinuria (PNH)
- Roche’s BTK inhibitor fenebrutinib significantly reduced brain lesions in people with relapsing forms of multiple sclerosis
- FDA accepts application for Roche’s Vabysmo for the treatment of retinal vein occlusion (RVO)
- Roche launches Institute of Human Biology to accelerate breakthroughs in R&D by unlocking the potential of human model systems
- CHMP recommends EU approval of Roche’s fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma
- [Ad-hoc-Mitteilung gemäss Art. 53 LR] Roche erzielt im ersten Quartal ein starkes Verkaufswachstum im Basisgeschäft beider Divisionen; Rückgang der Konzernverkäufe aufgrund der erwartungsgemäss geringeren Nachfrage nach COVID-19-Tests
- [Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth in base business of both divisions in the first quarter; Group sales decline due to expected drop in demand for COVID-19 tests
- [Annonce événementielle selon l’art. 53 RC] Roche annonce une forte croissance des ventes dans les activités de base de ses deux divisions au T1 ; le recul des ventes du Groupe est dû à la baisse attendue de la demande de tests COVID-19
- New Vabysmo data suggest greater retinal drying versus aflibercept in nAMD and DME
- [Ad hoc announcement pursuant to Art. 53 LR] FDA approves Roche’s Polivy in combination with R-CHP for people with certain types of previously untreated diffuse large B-cell lymphoma
More ▼
Key statistics
On Friday, Roche Holding AG (RHO6:FRA) closed at 36.20, 13.64% above the 52 week low of 31.86 set on Mar 29, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 36.20 |
---|---|
High | 36.20 |
Low | 36.20 |
Bid | -- |
Offer | -- |
Previous close | 36.44 |
Average volume | 65.17 |
---|---|
Shares outstanding | 6.47bn |
Free float | 291.27m |
P/E (TTM) | 18.44 |
Market cap | 255.82bn USD |
EPS (TTM) | 2.14 USD |
Annual div (ADY) | 1.21 EUR |
---|---|
Annual div yield (ADY) | 3.31% |
Div ex-date | Mar 16 2023 |
Div pay-date | Mar 27 2023 |
Data delayed at least 15 minutes, as of Jun 09 2023 09:54 BST.
More ▼